Skip to main content
Clinical Trials/NCT03304613
NCT03304613
Completed
Not Applicable

Resilience Skills Self-Management for Chronic Pain.

University of Michigan1 site in 1 country300 target enrollmentNovember 16, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Spine Pain
Sponsor
University of Michigan
Enrollment
300
Locations
1
Primary Endpoint
Fibromyalgia Impact Questionnaire-Revised (FIQ-R)
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The investigators will conduct a randomized controlled trial of an 8-week resilience-enhanced CBT online self-management program for chronic pain plus usual care (PRISM), standard e-CBT self-management plus usual care (e-CBT), and usual care alone. Thus, 300 individuals with chronic pain will undergo a comprehensive pre-intervention assessment that includes a blood draw (T1). Participants will then be randomized 2:2:1 as follows: e-CBT (n=120), PRISM (n=120) and usual care (n = 60). Immediately post-intervention (T2) and at 6 months (T3) and 12 months (T4) after that, participants undergo the same in-person assessment including blood draw. Telomerase activity will be assessed at T1, T2 and T3; and telomere length at T1 and T4

Registry
clinicaltrials.gov
Start Date
November 16, 2017
End Date
March 21, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Afton Hassett, Psy.D.

Associate Research Scientist

University of Michigan

Eligibility Criteria

Inclusion Criteria

  • Primary back or spine pain diagnosis from the Back \& Pain Center at University of Michigan.
  • High scores on the 2011 survey criteria for Fibromyalgia. The survey criteria for FM consist of an assessment of widespread pain and symptom severity.

Exclusion Criteria

  • Co-morbid autoimmune disorders, including rheumatoid arthritis and systemic lupus erythematosus.
  • Medical conditions that can impair health status independent of spine pain and FM, including cardiopulmonary disorders (e.g. CHF, COPD), uncontrolled endocrine or allergic disorders (e.g., thyroid dysfunction, Type I diabetes), or malignancy within the preceding 2 years
  • Current psychotic disorder (schizophrenia, etc.), dissociative identity disorder, untreated bipolar disorder, active suicide risk, or current alcohol / drug dependence.
  • Planned major surgery in the next 12 months;
  • Pregnancy or taking steroid medications
  • Recent pain interventions ≤6 weeks prior to study (e.g., back surgery, epidural steroid injections) or planned interventions for the study period (e.g., surgery scheduled). Ongoing physical therapy will be allowed and new physical therapy or exercise regimen will be addressed during data analysis;
  • Cognitive impairment or dementia (inability to give consent or meaningfully participate);
  • Pending or recently received (within 1 years) pain-related disability or Workman's Compensation;
  • Unable to read or fluently converse in English;
  • Planning to move from the area in next 14 months;

Outcomes

Primary Outcomes

Fibromyalgia Impact Questionnaire-Revised (FIQ-R)

Time Frame: At 8-week assessment point

The Fibromyalgia Impact Questionnaire-Revised (FIQR) assesses the total spectrum of problems and responses to therapy. The 2009 revised version contains 21 items assessing broad domains such as physical function, overall impact, and a wide range of symptoms. The measure is self-report with a recall period of the past week and requires only several minutes to complete.

Secondary Outcomes

  • Brief Pain Inventory (BPI)(At 8-week assessment point)
  • Pain Catastrophizing Scale (PCS)(At 8-week assessment point)
  • Patient Health Questionnaire 9-item (PHQ-9):(At 8-week assessment point)
  • Generalized Anxiety Disorder 7-item (GAD-7)(At 8-week assessment point)
  • Pittsburgh Sleep Quality Index (PSQI)(At 8-week assessment point)
  • PROMIS Fatigue-Short Form(At 8-week assessment point)
  • Multidimensional Inventory of Subjective Cognitive Impairment (MISCI)(At 8-week assessment point)
  • Perceived Stress Scale (PSS)(At 8-week assessment point)
  • Telomerase activity as measured by the Droplet Digital PCR (ddPCR) method(At 8-week assessment point)
  • Telomere length(At 1 year assessment point)
  • Subjective well-being(At 8-week assessment point)
  • Six-Minute Walk Test (6MWT)(At 8-week assessment point)
  • Sit-to-Stand Test(At 8-week assessment point)

Study Sites (1)

Loading locations...

Similar Trials